Skip to main content
SpringerLink
Log in

Dapagliflozin: a guide to its use in type 2 diabetes mellitus

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Dapagliflozin (Forxiga®), the first available renal sodium-glucose co-transporter-2 inhibitor, is a glucose-lowering agent with a unique insulin-independent mechanism of action. Relative to placebo, oral dapagliflozin significantly reduced glycated haemoglobin and fasting plasma glucose values when administered as monotherapy in previously untreated patients with type 2 diabetes mellitus, and as add-on therapy in patients with inadequately controlled type 2 diabetes despite treatment with oral antidiabetic agents or insulin-based therapy. Dapagliflozin is generally well tolerated with a low propensity to cause hypoglycaemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.

    Article  PubMed  CAS  Google Scholar 

  2. American Diabetes Association. Standards of medical care in diabetes: 2012. Diabetes Care. 2012;35(Suppl 1):S11–63.

    Google Scholar 

  3. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.

    Article  PubMed  CAS  Google Scholar 

  4. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol. 2008;18(3):222–9.

    Article  PubMed  Google Scholar 

  5. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34–42.

    Article  PubMed  CAS  Google Scholar 

  6. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–85.

    Article  PubMed  CAS  Google Scholar 

  7. Forxiga (dapaglifloxin) 5 mg & 10 mg film coated tablets: summary of product characteristics. London: European Medicines Agency; 2012.

  8. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–24.

    Article  PubMed  Google Scholar 

  9. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–33.

    Article  PubMed  CAS  Google Scholar 

  10. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–38.

    Article  PubMed  CAS  Google Scholar 

  11. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–15.

    Article  PubMed  Google Scholar 

  12. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–22.

    Article  PubMed  CAS  Google Scholar 

  13. Wilding JP, Norwood P, T’Joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–62.

    Article  PubMed  CAS  Google Scholar 

  14. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31.

    Article  PubMed  CAS  Google Scholar 

  15. Rohwedder K, Mansfield T, Martin P, et al. Durability of dapagliflozin treatment response in patients with T2DM: 2-year results [abstract no. 1030-P]. 72nd Annual Meeting of the American Diabetes Association; 8–12 Jun 2012.

  16. Bailey CJ, Gross JL, Hennicken D, et al. Dapaglifloxin add-on to metformin in type 2 diabetees inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.

    Article  PubMed  CAS  Google Scholar 

  17. Johnsson K PA, Apanovitch A, et al. Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus [abstract no. 743]. European Association for the Study of Diabetes, Berlin; 1–5 Oct 2012.

  18. Ptaszynska A, Chalamandaris A-G, Sugg J, et al. Dapagliflozin does not impact renal function in patients with type 2 diabetes [abstract no. 242]. Annual Meeting of the European Association for the Study of Diabetes, Berlin; 1–5 Oct 2012.

  19. Kohan D, Fioretto P, List J, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract no. TH-PO524]. J Am Soc Nephrol. 2011;22:232A.

    Google Scholar 

  20. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990–9.

    Article  PubMed  CAS  Google Scholar 

  21. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin [abstract no. 748]. Annual Meeting of the European Association for the Study of Diabetes, Berlin; 1–5 Oct 2012.

Download references

Acknowledgement

The manuscript was reviewed by: B.M. Cheung, Department of Medicine, University of Hong Kong, Hong Kong; D. Cucinotta, Department of Internal Medicine, University of Messina, Messina, Italy; P.M. Nilsson, Section of Medicine, Department of Clinical Sciences, University Hospital, Malmö, Sweden.

Disclosure

This article was updated from Drugs 2012;72(17):2289–312 [3]. The preparation of this review was not supported by any external funding. During the review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Mary Hines, Katherine A. Lyseng-Williamson & Greg L. Plosker

Authors
  1. Mary Hines
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hines, M., Lyseng-Williamson, K.A. & Plosker, G.L. Dapagliflozin: a guide to its use in type 2 diabetes mellitus. Drugs Ther Perspect 29, 194–199 (2013). https://doi.org/10.1007/s40267-013-0045-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-013-0045-9

Keywords

Search

Navigation